DVA
DaVita Inc.
Set alert
- YTD
- +65.04%
- 1 year
- +57.89%
- Open
- 175.00
- Prev close
- 193.31
- Mkt cap
- 11.96B
- Vol
- 1.76M
- Avg vol
- 807.76K
- EPS
- 11.84
- P/E
- 15.84
- Div yield
- 0.00%
More statistics
- Low
- 173.28
- High
- 187.77
- Forward P/E
- 10.95
- Beta
- 0.80
- Short ratio
- 7.53
- Inst. own
- 48.43%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 1, 2027
- 50-d avg
- 181.16
- 200-d avg
- 176.60
- 1y target
- 219.86
Key statistics
- Market cap
- 12.04B
- Enterprise value
- 26.90B
- Trailing P/E
- 15.85
- Forward P/E
- 10.95
- PEG ratio
- 0.47
- Price / sales
- 0.86
- Price / book
- 0.00
- EPS (TTM)
- 11.84
- Beta
- 0.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 6.05%
- Revenue (TTM)
- 14.01B
- Revenue growth
- 5.20%
- Free cash flow
- 1.04B
- Total cash
- 688.88M
- Total debt
- 13.41B
- Return on equity
- 88.48%
- Shares outstanding
- 64.19M
- Short % of float
- 15.12%
- 50-day average
- 181.16
- 200-day average
- 176.60
Analyst view
Consensus: buy
- Target (low)
- 165.00
- Target (mean)
- 219.86
- Target (high)
- 270.00
- Strong buy0
- Buy3
- Hold4
- Sell0
- Strong sell1
Next earnings
Feb 1, 2027
Expected Feb 1, 2027. Consensus EPS estimate 4.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 1, 2027 | Dec 30, 2026 | 4.40 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 3.57 | 3.82 | +0.25 | +7.00% |
| Aug 4, 2026 | Jun 30, 2026 | 3.88 | 4.02 | +0.14 | +3.61% |
| May 5, 2026 | Mar 31, 2026 | 2.41 | 2.87 | +0.46 | +19.09% |
| Feb 2, 2026 | Dec 31, 2025 | 3.24 | 3.40 | +0.16 | +4.94% |
| Oct 29, 2025 | Sep 30, 2025 | 3.17 | 2.51 | -0.66 | -20.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | TD Cowen | up | Hold | Buy |
| Aug 7, 2026 | Truist Securities | main | Hold | Hold |
| Aug 5, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Jul 14, 2026 | Truist Securities | main | Hold | Hold |
| Jul 10, 2026 | UBS | main | Buy | Buy |
| Jul 9, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United States
- Website
- davita.com
News
- DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y
- What DaVita (DVA) Said on Its Q3 Earnings Call
- DaVita Inc. (DVA) Q3 2026 Earnings Call Transcript
- DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates
- DaVita Q3 2026 Earnings Call Transcript
- DaVita Q3 2026 Earnings Call Transcript
- DaVita Q3 Adj. EPS $3.82 Beats $3.61 Estimate, Sales $3.578B Beat $3.508B Estimate
- DaVita Inc. 3rd Quarter 2026 Results
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA
Your note
Sign in to keep a note on DVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ACKERMAN JOEL | Chief Financial Officer | Sale | May 6, 2026 | 132,434 |
| ARWAY PAMELA M. | Director | Stock Award(Grant) | Aug 13, 2026 | 27,223 |
| BERG CHARLES G | Director | Stock Award(Grant) | May 14, 2025 | 27,029 |
| BERKSHIRE HATHAWAY, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 26, 2026 | 0 |
| BERRY CHRISTOPHER MICHAEL | Officer | Stock Award(Grant) | Mar 12, 2026 | 19,640 |
| DESOER BARBARA J | Director | Stock Award(Grant) | Aug 13, 2026 | 14,299 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Berkshire Hathaway, Inc | 45.27% | 28,880,209 | 5.42B | Jun 29, 2026 |
| Blackrock Inc. | 3.86% | 2,460,987 | 461.80M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.29% | 2,101,425 | 394.33M | Jun 29, 2026 |
| Morgan Stanley | 2.51% | 1,601,710 | 300.56M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.16% | 1,377,914 | 258.57M | Jun 29, 2026 |
| State Street Corporation | 2.07% | 1,323,019 | 248.26M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 1.68% | 1,068,917 | 200.58M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.60% | 1,019,274 | 191.27M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 1.30% | 830,137 | 155.78M | Jun 29, 2026 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Quality Equity Fund | 1.16% | 738,864 | 138.65M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.15% | 736,440 | 138.19M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 0.73% | 466,341 | 87.51M | Jun 29, 2026 |